Pfizer’s Next Lyme Shot: What a Fifth-Dose VLA15 Trial Signals for PFE Investors

Pfizer Inc (PFE) announced an update on their ongoing clinical study.

The study, formally titled “A Phase 3, Randomized, Placebo-Controlled, Double-Blinded Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine, VLA15, in Healthy Participants ≥7 Years of Age,” aims to see how well a fifth dose of Pfizer’s Lyme vaccine works and how safe it is over time. It targets people already given four doses, so results speak to long-term protection in a real-world style group.

The main treatment is VLA15, a six-type Lyme vaccine designed to prevent infection before it starts. It’s compared with a simple saline shot, which acts as an inactive control, so any benefit seen can be tied back to the vaccine itself.

The trial is interventional and in Phase 3, with people randomly assigned to get either VLA15 or placebo. It uses a parallel design and triple blinding, meaning patients, doctors, and assessors do not know who gets what, and the core goal is to see if the vaccine can prevent Lyme disease safely.

Participants receive one shot in the arm, either one or two years after their fourth VLA15 dose, and are followed for about 12 months. Across four visits, they get health checks and blood tests, letting researchers track safety signals and immune responses over time without heavy burden on patients.

The study opened for submissions on 23 March 2026, marking the formal start of operational planning and early recruitment. The most recent update filed on 4 May 2026 signals that Pfizer (PFE) is actively managing the trial, a useful sign for investors watching execution risk and data timing.

For markets, Lyme disease prevention is a growing niche as tick exposure rises in the U.S. and Europe, and a successful VLA15 program could add a new seasonal revenue stream for Pfizer in the back half of the decade. It may also pressure rivals in vaccines and smaller Lyme-focused biotechs, as a large, branded product from PFE tends to pull share and shape payer expectations.

In the near term, the update mainly supports sentiment that Pfizer is pushing ahead on post-pandemic vaccines to diversify beyond COVID-19, which can help stabilize the valuation narrative. Strong Phase 3 booster data would likely be read as proof of durable demand, while safety issues or weak protection could weigh on the stock and lift perceived opportunity for competitors.

Overall, this Phase 3 booster study of VLA15 remains active and under recruitment, and investors can track further revisions and timing details through the ongoing listing on the ClinicalTrials portal.

To learn more about PFE’s potential, visit the Pfizer Inc drug pipeline page.